projections

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Starbox Group’s StarboxAI – ViPro Module: Transforming Content Creation

Source Node:
Time Stamp: September 5, 2023 12:41 PM - Modified On: September 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Kuala Lumpur, Malaysia, Sept 5th, 2023 – Starbox Group Holdings Ltd. (Nasdaq: STBX), a dynamic player in cash rebates, digital advertising, and payment solutions, with a vision of leading in artificial intelligence (“AI”) solutions throughout Southeast Asia, is making waves with the launch of its groundbreaking StarboxAI - ViPro module. This innovative module introduces a text-to-video feature set to redefine content creation. The Text-to-Video feature within the StarboxAI - ViPro module is not just an addition; it's a revelation. It empowers content creators to seamlessly transmute textual instructions or scripts

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Source Node:
Time Stamp: August 29, 2023 11:37 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Livento Group, Inc. Announces Second Quarter Results with Revenue Growth of Over 90%, Including Significant Achievements and Updates

Source Node:
Time Stamp: August 17, 2023 3:06 PM - Modified On: August 17, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK, NY / August 14, 2023 / NuGene International, Inc./Livento Group, Inc. (OTC Pink:NUGN), a dynamic leader specializing in the acquisition and development of companies with disruptive business models in film, content, and technology sectors, is pleased to announce revenue growth of 91.65% for the second quarter of 2023, compared to the same period in 2022. Financial Highlights: Revenue Growth:The second quarter ending June 30, 2023, saw revenues of $431,184, up from $224,986 in 2022. For the six-month period ending June 30, 2023, revenues grew from $680,202 to $922,651, a growth of

GPOPPLUS (GPOX:US:OTC) Announces Impressive Revenue Results

Source Node:
Time Stamp: August 1, 2023 5:58 AM - Modified On: August 1, 2023 - Published By:
Source Cluster:
Republished By Plato

GPOPlus+, (GPOX:US:OTC) a leading provider and distributor of products for convenience stores and specialty retailers, gas stations, smoke shops, has recently announced an impressive surge in revenues during the fourth quarter of the year. The company reported a staggering 320% increase in its financial performance, marking a significant milestone for the organization. GPOPlus+ offers a unique technology driven direct store delivery model (“DSD”) that is creating both significant increases in revenue as well as improved unit economics with greater efficiencies yielding higher margins.  The Company has implemented this program successfully

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Wikisoft Corp. signs Letter of Intent to Acquire Disruptive Blockchain Tech Company – Etheralabs LLC.

Source Node:
Time Stamp: February 9, 2022 10:25 AM - Modified On: February 9, 2022 - Published By:
Source Cluster:
Republished By Plato

San Francisco, February 9, 2022 - Wikisoft Corp. (the “Company,” “we,” and “our”) (OTCQB: WSFT) today announced that it has entered into a non-binding letter of intent to acquire a majority stake in Etheralabs LLC, a New York City based venture lab and ecosystem that invests in, builds, and deploys disruptive technologies across the Blockchain space. The proposed transaction would include full global access to Etheralabs LLC’s disruptive technologies across the Blockchain and global funding landscape. With the majority stake, Wikisoft plans to ensure that Etheralabs future product and technology roadmap supports Wikisoft´s